Article (Scientific journals)
Final Height in Children with Idiopathic Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: The Belgian Experience
Thomas, M.; Massa, G.; Bourguignon, Jean-Pierre et al.
2001In Hormone Research in Paediatrics, 55 (2), p. 88-94
Peer Reviewed verified by ORBi
 

Files


Full Text
FINAL HEIGHT IN CHILDREN _Bourguignon_2001.pdf
Author postprint (449.76 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Growth hormone deficiency; Growth hormone treatment; Final height; Idiopathic hypopituitarism; Puberty; Belgium
Abstract :
[en] BACKGROUND: The growth response to recombinant hGH (rhGH) treatment and final height of 61 Belgian children (32 boys) with idiopathic growth hormone deficiency (GHD) were studied. PATIENTS/METHODS: Two patient groups were compared: Group 1 with spontaneous puberty (n = 49), Group 2 with induced puberty (n = 12). The patients were treated with daily subcutaneous injections of rhGH in a dose of 0.5-0.7 IU/kg/week (0.17-0.23 mg/kg/week) from the mean +/- SD age of 11.9 +/- 3.1 years during 5.1 +/- 2.1 years. RESULTS: rhGH treatment induced a doubling of the height velocity during the first year and resulted in a normalisation of height in 53 (87%) patients. Final height was -0.7 +/- 1.1 SDS, being 170.4 +/- 7.2 cm in boys and 158.0 +/- 6.4 cm in girls. Corrected for mid-parental height, final height was 0.0 +/- 1.1 SDS. Ninety-two percent of the patients attained an adult height within the genetically determined target height range. Although height gain during puberty was smaller in the patients with induced puberty (boys: 17.1 +/- 7.0 cm vs. 27.5 +/- 6.6 cm (p < 0.005); girls: 9.6 +/- 7.4 cm vs. 22.2 +/- 6.1 cm (p < 0.005)), no differences in final height after adjustment for mid-parental height were found between patients with spontaneous or induced puberty. CONCLUSIONS: We conclude that patients with idiopathic GHD treated with rhGH administered as daily subcutaneous injections in a dose of 0.5-0.7 IU/kg/week reach their genetic growth potential, resulting in a normalisation of height in the majority of them, irrespective of spontaneous or induced puberty. Copyright © 2001 S. Karger AG, Basel
Research Center/Unit :
The Belgian Study Group for Paediatric Endocrinology - BSGPE
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Thomas, M.
Massa, G.
Bourguignon, Jean-Pierre ;  Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Craen, M.
De Schepper, J.
de Zegher, F.
Dooms, L.
Du Caju, M.
Francois, I.
Heinrichs, C.
Malvaux, P.
Rooman, R.
Thiry-Counson, G.
Vandeweghe, M.
Maes, M.
More authors (5 more) Less
Language :
English
Title :
Final Height in Children with Idiopathic Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: The Belgian Experience
Publication date :
2001
Journal title :
Hormone Research in Paediatrics
ISSN :
1663-2818
eISSN :
1663-2826
Publisher :
Karger, Basel, Switzerland
Volume :
55
Issue :
2
Pages :
88-94
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
The Foundation of the Belgian Study Group for Paediatric Endocrinology
Available on ORBi :
since 22 February 2021

Statistics


Number of views
76 (7 by ULiège)
Number of downloads
145 (7 by ULiège)

Scopus citations®
 
45
Scopus citations®
without self-citations
39
OpenCitations
 
22
OpenAlex citations
 
49

Bibliography


Similar publications



Contact ORBi